189 related articles for article (PubMed ID: 35978838)
1. What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
Petrylak DP; Watkins SP; Loehr A
Front Oncol; 2022; 12():951348. PubMed ID: 35978838
[TBL] [Abstract][Full Text] [Related]
2. Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.
Loehr A; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Hussain A; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Dowson M; Golsorkhi T; Chowdhury S; Abida W
Clin Cancer Res; 2021 Dec; 27(24):6677-6686. PubMed ID: 34598946
[TBL] [Abstract][Full Text] [Related]
3. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
Loehr A; Hussain A; Patnaik A; Bryce AH; Castellano D; Font A; Shapiro J; Zhang J; Sautois B; Vogelzang NJ; Chatta G; Courtney K; Harzstark A; Ricci F; Despain D; Watkins S; King C; Nguyen M; Simmons AD; Chowdhury S; Abida W
Eur Urol; 2023 Mar; 83(3):200-209. PubMed ID: 36243543
[TBL] [Abstract][Full Text] [Related]
4. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W; Campbell D; Patnaik A; Bryce AH; Shapiro J; Bambury RM; Zhang J; Burke JM; Castellano D; Font A; Ganju V; Hardy-Bessard AC; McDermott R; Sautois B; Spaeth D; Voog E; Piulats JM; Pintus E; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Loehr A; Despain D; Simmons AD; Dowson M; Go J; Watkins SP; Chowdhury S
Eur Urol; 2023 Sep; 84(3):321-330. PubMed ID: 37277275
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Simmons AD; Nguyen M; Pintus E
BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
[TBL] [Abstract][Full Text] [Related]
6. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Abida W; Campbell D; Patnaik A; Shapiro JD; Sautois B; Vogelzang NJ; Voog EG; Bryce AH; McDermott R; Ricci F; Rowe J; Zhang J; Piulats JM; Fizazi K; Merseburger AS; Higano CS; Krieger LE; Ryan CJ; Feng FY; Simmons AD; Loehr A; Despain D; Dowson M; Green F; Watkins SP; Golsorkhi T; Chowdhury S
Clin Cancer Res; 2020 Jun; 26(11):2487-2496. PubMed ID: 32086346
[TBL] [Abstract][Full Text] [Related]
7. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
8. Differential Activity of PARP Inhibitors in
Taza F; Holler AE; Fu W; Wang H; Adra N; Albany C; Ashkar R; Cheng HH; Sokolova AO; Agarwal N; Kessel A; Bryce A; Nafissi N; Barata P; Sartor AO; Bastos D; Smaletz O; Berchuck JE; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Su C; Marshall CH; Antonarakis ES
JCO Precis Oncol; 2021; 5():. PubMed ID: 34778690
[TBL] [Abstract][Full Text] [Related]
9. A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a
Sautois B; Loehr A; Watkins SP; Schroeder H; Abida W
Curr Oncol; 2022 Jun; 29(6):4178-4184. PubMed ID: 35735442
[TBL] [Abstract][Full Text] [Related]
10. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
Abida W; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Loehr A; Dowson M; Golsorkhi T; Chowdhury S;
J Clin Oncol; 2020 Nov; 38(32):3763-3772. PubMed ID: 32795228
[TBL] [Abstract][Full Text] [Related]
11. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Orme JJ; Taza F; De Sarkar N; Tewari AK; Arsalan Naqvi S; Riaz IB; Childs DS; Omar N; Adra N; Ashkar R; Cheng HH; Schweizer MT; Sokolova AO; Agarwal N; Barata P; Sartor O; Bastos D; Smaletz O; Berchuck JE; McClure H; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Mehra N; Nelson PS; Hwang J; Dehm SM; Shi Q; Fleischmann Z; Sokol ES; Elliott A; Huang H; Bryce A; Marshall CH; Antonarakis ES
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38072760
[TBL] [Abstract][Full Text] [Related]
12. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
13. Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations.
Wu MS; Goldberg H
Cancer Manag Res; 2022; 14():3159-3174. PubMed ID: 36411744
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.
Labadie BW; Morris DS; Bryce AH; Given R; Zhang J; Abida W; Chowdhury S; Patnaik A
Cancer Manag Res; 2022; 14():673-686. PubMed ID: 35210863
[TBL] [Abstract][Full Text] [Related]
15. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Kói T; Ács N; Hegyi P; Hadaschik B; Nyirády P; Szarvas T
Eur Urol Oncol; 2024 Jun; 7(3):365-375. PubMed ID: 37722977
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Anscher MS; Chang E; Gao X; Gong Y; Weinstock C; Bloomquist E; Adeniyi O; Charlab R; Zimmerman S; Serlemitsos-Day M; Ning YM; Mayrosh R; Fuller B; Trentacosti AM; Gallagher P; Bijwaard K; Philip R; Ghosh S; Fahnbulleh F; Diggs F; Arora S; Goldberg KB; Tang S; Amiri-Kordestani L; Pazdur R; Ibrahim A; Beaver JA
Oncologist; 2021 Feb; 26(2):139-146. PubMed ID: 33145877
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.
Coquan E; Penel N; Lequesne J; Leman R; Lavaud P; Neviere Z; Brachet PE; Meriaux E; Carnot A; Boutrois J; Castera M; Goardon N; Muller E; Leconte A; Thiery-Vuillemin A; Clarisse B; Joly F
Ther Adv Urol; 2024; 16():17562872241229876. PubMed ID: 38425504
[TBL] [Abstract][Full Text] [Related]
19. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
20. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]